Ionis is rated a Buy with a valuation offering attractive upside despite reimbursement, competition, and execution risks. Read more on IONS stock here.
Investment Thesis I initiate coverage of Ionis Pharmaceuticals, Inc. (IONS) with a Buy rating. Recently, the shares sold off following the two July 2026 setbacks: a) the phase 3 CARDIO-TTRansform trial of I initiate coverage of Ionis Pharmaceuticals, Inc. (IONS) with a Buy rating. Recently, the shares sold off following the two July 2026 setbacks: a) the phase 3 CARDIO-TTRansform trial of Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in IONS over the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I do not provide personal investment advice. All content in this article, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpreted as financial or investment advice. While I strive to provide accurate and up-to-date information, the content may contain errors, inaccuracies, or omissions.
Any financial decisions or investments made based on the information presented in this article are solely at your own risk. I am not responsible for any financial losses, damages, or other consequences resulting from actions taken in reliance on the information provided. You should conduct your own due diligence and consult with a qualified financial professional before making any investment decisions.
This article reflects my personal views and opinions and is not affiliated with any employer, financial institution, or advisory firm. No representations or warranties are made regarding the completeness, accuracy, or reliability of the content, including any external links provided. Any third-party links are for informational purposes only, and I do not endorse or take responsibility for the content or services offered by external sources.
All information is provided on an "as is" basis without any express or implied warranties. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor.
Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party
Source and reference
authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Read original source- Published
- Jul 16, 2026
- Updated
- Jul 16, 2026
- Source
- Seeking Alpha
- Category
- Health
- Read time
- 2 min
Key facts
Why this matters locally
This health story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.
Local impact
BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.
Timeline
Source and credit
BC Post may summarize, organize, and add local context for reader clarity. Original reporting remains with the listed publisher.